Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Medcan FX01
- Development stage
- Unknown
- Lead developer
- Medcan Australia
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Medcan FX01 is a medicinal cannabis oil developed by Medcan Australia. It is formulated to contain 20 mg/mL of delta-9-tetrahydrocannabinol (THC) and approximately 1 mg/mL of cannabidiol (CBD), derived from the Afghan Kush indica strain. In Australia, Medcan FX01 is available as an unapproved therapeutic good via the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) and Authorised Prescriber pathways. It is primarily prescribed for the management of chronic pain, insomnia, and anxiety, leveraging the sedative, analgesic, and anxiolytic properties of THC through its action as a partial agonist on cannabinoid receptors CB1 and CB2.
- Brand names
- Medcan FX01
- Other names
- Medcan FX01 20:1 OilMedcan FX01 20mg THC Oil
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Medcan FX01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medcan FX01.